Tests cannabinoid drugs for symptoms in children with cancer
Tests cannabinoid drugs for side effects in children with cancer.
Plain-language title generated from the registry record
Registry title: CANnabinoids in Pediatric ONCology
Key facts
- Where
- Halifax, Toronto, and Vancouver, CanadaSee the 3 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers with relapsed or refractory cancer, including brain tumours, to test how well cannabinoids are tolerated.
- Age
- 4-17 years old at enrollment.
- Sex
- All sexes can join.
- Disease stage
- Relapsed or refractory solid or blood cancer, including brain tumours.
- Earlier treatment
- Must currently be receiving active cancer treatment or supportive and palliative care. Nabilone or other cannabis-based products within the past 2 weeks are not allowed.
Main reasons for not taking part
- History of heart disease or severe liver or kidney problems
- Use of nabilone or cannabis-based products in the past 2 weeks, or recreational cannabis use
- Personal or family history of schizophrenia or psychotic disorders, substance use disorder, or cannabinoid allergy
- Pregnant or breast/chest-feeding, or planning pregnancy within 3 months of study completion
- Currently receiving cell therapies or immune checkpoint inhibitors
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 4 and 18 years old?
Source: NCT05754840, who can take part
Where in Canada
- IWK Health CentreHalifax, CanadaContact: Bruce Crooks, MDTaking people
- The Hospital for Sick ChildrenToronto, CanadaContact: Adam Rapoport, MD, FRCPC, MHScTaking people
- BC Children ' s HospitalVancouver, CanadaContact: Rod Rassekh, MD, FRCPCTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Manitoba
- Trial code
- NCT05754840
- Record updated
- 11 June 2026
- Original description
CANnabinoids in Pediatric ONCology is a randomized, double blind, adaptive clinical trial looking at the tolerability of cannabinoids in children with cancer across 3 Canadian children's hospitals.Read full original descriptionShow less
A Randomized, Double-Blind Tolerability Trial of Cannabinoids for Symptom Management in Children With Cancer: the CAN-PONC Trial
CANnabinoids in Pediatric ONCology is a randomized, double blind, adaptive clinical trial looking at the tolerability of cannabinoids in children with cancer across 3 Canadian children's hospitals.
Inclusion: Ages 4-17 years old at the time of enrollment; Diagnosed with relapsed or refractory solid or hematologic malignancy including brain tumours; Currently receiving active cancer treatment or supportive and palliative care; Estimated survival of at least 4 months at the time of enrollment.
Exclusion: Participation in other clinical trials that prohibit the concurrent use of cannabis; Anyone who is currently receiving cell therapies or immune checkpoint inhibitors; Children with a personal or family history of schizophrenia or psychotic disorders, substance use disorder or allergy to cannabinoids or cannabis; History of cardiovascular disease, severe hepatic or renal impairment defined by alanine transaminase (ALT)/ aspartate aminotransferase (AST) more than 5x upper limit of normal (ULN), creatinine more than 5x ULN or glomerular filtration rate (GFR less than) <60 mL/min/1.73 m273m2, unstable/unmanaged arrhythmias, uncontrolled hypertension with blood pressure above 99th centile for age or history of myocardial infarction; Nabilone or other cannabis-based products use (including for recreational purposes) within the past 2 weeks or planned nabilone use for the duration of their enrollment in the trial. Current use/continued use of recreational cannabis, or not willing to abstain from recreational cannabis use during the trial; Anyone who is pregnant or breast/chest-feeding throughout the duration of the study or has the intention to become pregnant within 3 months of study completion; Unwilling or unable to use effective form of contraception and refrain from driving motorized vehicles (cars, motorcycles, boats, etc.) throughout the study period.